| |
|
|
|
|
|
|
|||
|
Blood, 1 April 2005, Vol. 105, No. 7, pp. 2620-2621.
Functional tissue factor in blood?VA BOSTON HEALTHCARE SYSTEM, HARVARD MEDICAL SCHOOL
Several lines of evidence suggest that blood-borne tissue factor can promote thrombus growth. This study demonstrates that the amount of functional tissue factor in the blood of healthy individuals under nonflow conditions is vanishingly small.
In live mice, it has been demonstrated that blood-borne tissue factor accumulates in newly formed thrombi via monocyte-derived microparticles in a process dependent upon P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1).3 To assess the functional significance of blood-borne tissue factor relative to vascular wall tissue factor under physiologic conditions, 2 groups have studied thrombus formation in bone marrow transplant chimeras of lowtissue factor mice and wild-type mice. Using intravital microscopy to study thrombus formation following laser-induced arterial injury, Chou et al4 concluded that tissue factor on hematopoietic cellassociated microparticles contributes significantly to thrombus propagation. However, Day et al5 found that thrombus formation following either carotid artery injury or inferior vena caval ligation was driven primarily by vascular wall tissue factor as opposed to blood-borne tissue factor. The reasons for the different results of the 2 studies are likely due to differences in the extent of vessel wall damage and the exposure of vessel wall tissue factor as well as the absence of circulating microparticles in a ligation thrombosis model.
In this issue of Blood, Butenas and colleagues provide convincing data that the level of functional tissue factor in nonflowing blood of healthy volunteers cannot exceed 20 fM. In addition, they were unable to identify tissue factor activity or antigen on quiescent or ionophore-stimulated platelets of healthy individuals. There is considerable interest in assessing the role of blood-borne tissue factor in the pathogenesis of hypercoagulable states in association with diseases such as cancer, sepsis, and sickle cell disease. A major challenge for the field will be the development of assays for measuring functional tissue factor forms in blood that are physiologically relevant. As pointed out by Butenas et al, one must be cautious in interpreting tissue factor activity assays that use very large (ie, supraphysiologic) amounts of added factor VIIa. There are clearly key mysteries that require unraveling with regard to the role of blood-borne tissue factor in the thrombotic process. References
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||